Log In | Shopping Cart | Advanced Search
            
  • Home
  • Career
  • Distributors
  • Contact Us:
  • Email: crm@excellgen.com
Products
Modified mRNA
Encapsulated mRNA
mRNA Enzyme
SARS-CoV-2
Pseudovirus
Popular Products
Cancer Proteins
Antibodies
DNA Binding Proteins
Electrophoresis
Genome Engineering
Polymerases
Recombinases
Transcription Factors
Transfection
Services
Modified mRNA
Custom Cloning
Virus Production
Protein Purification
Protein Expression
Pseudovirus
 Previous 
 Return to List 
 Next 

Lentivirus Pseudotyped with SARS-CoV-2 Spike Glycoprotein, United Kingdom Variant

Catalog #: EG-343


Please Choose:



Qty:

Product Name Lentivirus Pseudotyped with SARS-CoV-2 Spike Glycoprotein, HexaPro Stabilized Trimer, United Kingdom Variant
Description Lentivirus particles pseudotyped with SARS‑CoV‑2 spike glycoprotein, with hexaPro mutations so the surface protein antigenically optimal pre-fusion conformation, produced and purified from HEK 293 cells. This pseudovirus has N501Y mutation.
Mutations Furin site RRAR mutated to GSAS; HexaPro mutations (K986P, V987P, F817P, A892P, A899P and A942P) to ensure the S glycoprotein remains in an antigenically optimal pre-fusion conformation; United Kingdom mutations: N501Y
Source
HEK293T cells
Reporter
EGFP
Application
  • Screening of SARS‑CoV‑2 neutralizing antibodies
  • Assessment of vaccine efficacy
Titer > 1 X 107 RFU/ml or > 1 X 105 TU/ml
Shipping Dry ice
Storage -80 oC
References
    1. Efective screening of SARS‑CoV‑2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS‑CoV‑2 spike glycoprotein.  Sci Rep 10, 19076 (2020). doi:10.1038/s41598-020-76135-w
    2. Prospective Mapping of Viral Mutations that Escape Antibodies Used to Treat COVID-19. Science. 371 (2020): 850-854. doi: 10.1126/science.abf9302. PubMed: 33495308.

     
 Ask a Question 
 
 Home | Privacy Policy | Terms & Conditions | Online Price Policy | Shipping & Return

Copyright © 2007-2022  Excellgen, Inc. All rights reserved